SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date  of  Report  (Date of earliest event reported)       JUNE 10, 1996 

                                        ENZON, INC.

                  (Exact  name  of  registrant  as  specified  in its charter)




       DELAWARE                    0-12957              22-237286
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)



        20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (908) 980-4500




     (Former name or former address, if changed since last report)










ITEM 5.  OTHER EVENTS

          Enzon,  Inc.  ("Enzon"  or the "Company") announced that  it  has
exercised 150,000 warrants to purchase common stock of Neoprobe Corporation
and sold the stock for a net profit  of  approximately  $1  million,  after
payment  to  Neoprobe of the aggregate average exercise price of $10.50 per
share.  The warrants  were  part  of  the  compensation  Enzon received for
licensing its Single-Chain Antigen-Binding (SCA(R)) protein  technology  to
Neoprobe  for  use  with  Neoprobe's  Radioimmunoguided  Surgery  (RIGS(R))
product  under  the  license  agreement  originally  signed  in  1992.  The
warrants  were  due  to  expire  in  1996.  Enzon will also be entitled  to
receive additional payments per product  upon  the achievement of specified
development  milestones  and  royalties  on sales of  any  future  products
developed by Neoprobe that utilize Enzon's SCA technology.








                            SIGNATURES


     Pursuant to the requirements of the Securities  Exchange  Act of 1934,

the  Registrant  has duly caused this report to be signed on its behalf  by

the undersigned hereunto duly authorized.




Dated:  June 24, 1996




                                              ENZON, INC.
                                             (Registrant)

                                   By:   /s/KENNETH J. ZUERBLIS
                                         Kenneth J. Zuerblis
                                         Vice President, Finance
                                         and Chief Financial
                                         Officer